Genomic and epigenomic integrative subtypes of renal cell carcinoma in a Japanese cohort.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
16 Dec 2023
16 Dec 2023
Historique:
received:
06
06
2023
accepted:
01
12
2023
medline:
17
12
2023
pubmed:
17
12
2023
entrez:
16
12
2023
Statut:
epublish
Résumé
Renal cell carcinoma (RCC) comprises several histological types characterised by different genomic and epigenomic aberrations; however, the molecular pathogenesis of each type still requires further exploration. We perform whole-genome sequencing of 128 Japanese RCC cases of different histology to elucidate the significant somatic alterations and mutagenesis processes. We also perform transcriptomic and epigenomic sequencing to identify distinguishing features, including assay for transposase-accessible chromatin sequencing (ATAC-seq) and methyl sequencing. Genomic analysis reveals that the mutational signature differs among the histological types, suggesting that different carcinogenic factors drive each histology. From the ATAC-seq results, master transcription factors are identified for each histology. Furthermore, clear cell RCC is classified into three epi-subtypes, one of which expresses highly immune checkpoint molecules with frequent loss of chromosome 14q. These genomic and epigenomic features may lead to the development of effective therapeutic strategies for RCC.
Identifiants
pubmed: 38104198
doi: 10.1038/s41467-023-44159-1
pii: 10.1038/s41467-023-44159-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8383Subventions
Organisme : Japan Agency for Medical Research and Development (AMED)
ID : 21ck0106547h000
Informations de copyright
© 2023. The Author(s).
Références
Linehan, W. M. Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res. 22, 2089–2100 (2012).
pubmed: 23038766
pmcid: 3483538
doi: 10.1101/gr.131110.111
Moch, H. et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours. Eur. Urol. 82, 458–468 (2022).
Capitanio, U. et al. Epidemiology of renal cell carcinoma. Eur. Urol. 75, 74–84 (2019).
pubmed: 30243799
doi: 10.1016/j.eururo.2018.08.036
Scelo, G. et al. Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat. Commun. 5, 5135 (2014).
pubmed: 25351205
doi: 10.1038/ncomms6135
Huang, Y. et al. Clonal architectures predict clinical outcome in clear cell renal cell carcinoma. Nat. Commun. 10, 1245 (2019).
pubmed: 30886153
pmcid: 6423009
doi: 10.1038/s41467-019-09241-7
Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 18, 1009–1021 (2017).
pubmed: 28694034
doi: 10.1016/S1470-2045(17)30516-8
Ricketts, C. J. et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 23, 313–326.e5 (2018).
pubmed: 29617669
pmcid: 6075733
doi: 10.1016/j.celrep.2018.03.075
Linehan, W. M. et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl. J. Med. 374, 135–145 (2016).
pubmed: 26536169
doi: 10.1056/NEJMoa1505917
Davis, C. F. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 26, 319–330 (2014).
pubmed: 25155756
pmcid: 4160352
doi: 10.1016/j.ccr.2014.07.014
Komai, Y. et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 15, 1170–1176 (2009).
pubmed: 19228722
doi: 10.1158/1078-0432.CCR-08-1183
Argani, P. MiT family translocation renal cell carcinoma. Semin. Diagn. Pathol. 32, 103–113 (2015).
pubmed: 25758327
doi: 10.1053/j.semdp.2015.02.003
Zhang, S. et al. Systematic chromatin accessibility analysis based on different immunological subtypes of clear cell renal cell carcinoma. Front. Oncol. 11, 575425 (2021).
pubmed: 33937014
pmcid: 8085385
doi: 10.3389/fonc.2021.575425
Chen, F. et al. Multilevel genomics-based taxonomy of renal cell carcinoma. Cell Rep. 14, 2476–2489 (2016).
pubmed: 26947078
pmcid: 4794376
doi: 10.1016/j.celrep.2016.02.024
Linehan, W. M. & Ricketts, C. J. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat. Rev. Urol. 16, 539–552 (2019).
pubmed: 31278395
doi: 10.1038/s41585-019-0211-5
The Cancer Genome Atlas Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49 (2013).
doi: 10.1038/nature12222
Sato, Y. et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat. Genet. 45, 860–867 (2013).
pubmed: 23797736
doi: 10.1038/ng.2699
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response rate to PD-1 inhibition. N Engl. J. Med. 377, 2500–2501 (2017).
pubmed: 29262275
pmcid: 6549688
doi: 10.1056/NEJMc1713444
Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).
Fridman, W. H., Zitvogel, L., Sautès-Fridman, C. & Kroemer, G. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).
pubmed: 28741618
doi: 10.1038/nrclinonc.2017.101
Braun, D. A. et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat. Med. 26, 909–918 (2020).
pubmed: 32472114
pmcid: 7499153
doi: 10.1038/s41591-020-0839-y
Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801–806 (2018).
pubmed: 29301960
pmcid: 6035749
doi: 10.1126/science.aan5951
Liu, X. D. et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat. Commun. 11, 2135 (2020).
pubmed: 32358509
pmcid: 7195420
doi: 10.1038/s41467-020-15959-6
Morrison, J. et al. Evaluation of whole-genome DNA methylation sequencing library preparation protocols. Epigenet. Chromatin 14, 28 (2021).
doi: 10.1186/s13072-021-00401-y
Wang, X. M. et al. Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus. Nat. Commun. 11, 739 (2020).
pubmed: 32029730
pmcid: 7005298
doi: 10.1038/s41467-020-14601-9
Delahunt, B. et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am. J. Surg. Pathol. 37, 1490–1504 (2013).
pubmed: 24025520
doi: 10.1097/PAS.0b013e318299f0fb
Lew, J. Q., Chow, W. H., Hollenbeck, A. R., Schatzkin, A. & Park, Y. Alcohol consumption and risk of renal cell cancer: the NIH-AARP diet and health study. Br. J. Cancer 104, 537–541 (2011).
pubmed: 21245859
pmcid: 3049576
doi: 10.1038/sj.bjc.6606089
Song, D. Y., Song, S., Song, Y. & Lee, J. E. Alcohol intake and renal cell cancer risk: a meta-analysis. Br. J. Cancer 106, 1881–1890 (2012).
pubmed: 22516951
pmcid: 3364130
doi: 10.1038/bjc.2012.136
Edenberg, H. J. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res. Health 30, 5–13 (2007).
pubmed: 17718394
pmcid: 3860432
Degasperi, A. et al. Substitution mutational signatures in whole-genome-sequenced cancers in the UK population. Science 376, eabl9283 (2022).
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
pubmed: 32025018
pmcid: 7054213
doi: 10.1038/s41586-020-1943-3
Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science 362, eaav1898 (2018).
Bentsen, M. et al. ATAC-seq footprinting unravels kinetics of transcription factor binding during zygotic genome activation. Nat. Commun. 11, 4267 (2020).
pubmed: 32848148
pmcid: 7449963
doi: 10.1038/s41467-020-18035-1
Argani, P. et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am. J. Surg. Pathol. 27, 750–761 (2003).
pubmed: 12766578
doi: 10.1097/00000478-200306000-00005
Sun, G. et al. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nat. Commun. 12, 5262 (2021).
pubmed: 34489456
pmcid: 8421377
doi: 10.1038/s41467-021-25618-z
Hinze, C. et al. Kidney single-cell transcriptomes predict spatial corticomedullary gene expression and tissue osmolality gradients. J. Am. Soc. Nephrol. 32, 291–306 (2021).
pubmed: 33239393
doi: 10.1681/ASN.2020070930
Hinze, C. et al. GRHL2 is required for collecting duct epithelial barrier function and renal osmoregulation. J. Am. Soc. Nephrol. 29, 857–868 (2018).
pubmed: 29237740
doi: 10.1681/ASN.2017030353
Auden, A. et al. Spatial and temporal expression of the Grainyhead-like transcription factor family during murine development. Gene Expr. Patterns 6, 964–970 (2006).
pubmed: 16831572
doi: 10.1016/j.modgep.2006.03.011
Jacobs, J. et al. The transcription factor Grainy head primes epithelial enhancers for spatiotemporal activation by displacing nucleosomes. Nat. Genet. 50, 1011–1020 (2018).
pubmed: 29867222
pmcid: 6031307
doi: 10.1038/s41588-018-0140-x
Huss, J. M., Garbacz, W. G. & Xie, W. Constitutive activities of estrogen-related receptors: transcriptional regulation of metabolism by the ERR pathways in health and disease. Biochim. Biophys. Acta 1852, 1912–1927 (2015).
pubmed: 26115970
doi: 10.1016/j.bbadis.2015.06.016
De Vitto, H., Bode, A. M. & Dong, Z. The PGC-1/ERR network and its role in precision oncology.NPJ Precis. Oncol. 3, 9 (2019).
pubmed: 30911677
pmcid: 6428848
doi: 10.1038/s41698-019-0081-6
Robbe, P. et al. Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. Nat. Genet. 54, 1675–1689 (2022).
pubmed: 36333502
pmcid: 9649442
doi: 10.1038/s41588-022-01211-y
Mitchell, T. J. et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell 173, 611–623.e17 (2018).
pubmed: 29656891
pmcid: 5927631
doi: 10.1016/j.cell.2018.02.020
Vinagre, J. et al. Frequency of TERT promoter mutations in human cancers. Nat. Commun. 4, 2185 (2013).
pubmed: 23887589
doi: 10.1038/ncomms3185
Fang, Y. et al. Protein expression of ZEB2 in renal cell carcinoma and its prognostic significance in patient survival. PLoS One 8, e62558 (2013).
pubmed: 23658743
pmcid: 3642198
doi: 10.1371/journal.pone.0062558
Gordan, J. D. et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14, 435–446 (2008).
pubmed: 19061835
pmcid: 2621440
doi: 10.1016/j.ccr.2008.10.016
Hoefflin, R. et al. HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat. Commun. 11, 4111 (2020).
pubmed: 32807776
pmcid: 7431415
doi: 10.1038/s41467-020-17873-3
Turajlic, S. et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 173, 595–610.e11 (2018).
pubmed: 29656894
pmcid: 5938372
doi: 10.1016/j.cell.2018.03.043
Wang, J. et al. Prognostic value of SETD2 expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. J. Urol. 196, 1363–1370 (2016).
pubmed: 27288695
doi: 10.1016/j.juro.2016.06.010
Liu, L. et al. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients. Biosci Trends 11, 214–220 (2017).
pubmed: 28260718
doi: 10.5582/bst.2016.01228
Klatte, T. et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol. Biomarkers Prev. 18, 894–900 (2009).
pubmed: 19240241
doi: 10.1158/1055-9965.EPI-08-0786
D’Avella, C., Abbosh, P., Pal, S. K. & Geynisman, D. M. Mutations in renal cell carcinoma. Urol. Oncol. 38, 763–773 (2020).
pubmed: 30478013
doi: 10.1016/j.urolonc.2018.10.027
Gulati, S. et al. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers. Eur. Urol. 66, 936–948 (2014).
pubmed: 25047176
pmcid: 4410302
doi: 10.1016/j.eururo.2014.06.053
Kanu, N. et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene 34, 5699–5708 (2015).
pubmed: 25728682
pmcid: 4660036
doi: 10.1038/onc.2015.24
Sun, X. et al. Infrequent mutation of ATBF1 in human breast cancer. J. Cancer Res. Clin. Oncol. 133, 103–105 (2007).
pubmed: 16932943
doi: 10.1007/s00432-006-0148-y
Sun, X. et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat. Genet. 37, 407–412 (2005).
pubmed: 15750593
doi: 10.1038/ng1528
Hariharasudhan, G. et al. TOPORS-mediated RAD51 SUMOylation facilitates homologous recombination repair. Nucleic Acids Res. 50, 1501–1516 (2022).
pubmed: 35061896
pmcid: 8860612
doi: 10.1093/nar/gkac009
Delahunt, B. & Eble, J. N. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod. Pathol. 10, 537–544 (1997).
pubmed: 9195569
Wang, X., Yang, Y. & Huycke, M. M. Commensal bacteria drive endogenous transformation and tumour stem cell marker expression through a bystander effect. Gut 64, 459–468 (2015).
pubmed: 24906974
doi: 10.1136/gutjnl-2014-307213
Zhang, H. & Fu, L. The role of ALDH2 in tumorigenesis and tumor progression: targeting ALDH2 as a potential cancer treatment. Acta Pharm. Sin B 11, 1400–1411 (2021).
pubmed: 34221859
pmcid: 8245805
doi: 10.1016/j.apsb.2021.02.008
Graff, R. E. et al. Type 2 diabetes in relation to the risk of renal cell carcinoma among men and women in two large prospective cohort studies. Diabetes Care 41, 1432–1437 (2018).
pubmed: 29678810
pmcid: 6014546
doi: 10.2337/dc17-2518
Habib, S. L., Prihoda, T. J., Luna, M. & Werner, S. A. Diabetes and risk of renal cell carcinoma. J. Cancer 3, 42–48 (2012).
pubmed: 22232697
doi: 10.7150/jca.3718
Argani, P. et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J. Clin. Oncol. 24, 1529–1534 (2006).
pubmed: 16575003
doi: 10.1200/JCO.2005.04.4693
Brannon, A. R. et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 1, 152–163 (2010).
pubmed: 20871783
pmcid: 2943630
doi: 10.1177/1947601909359929
Tu, L. et al. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival. Int. J. Cancer 147, 423–439 (2020).
pubmed: 31721169
doi: 10.1002/ijc.32785
Eschweiler, S. et al. Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. Nat. Immunol. 22, 1052–1063 (2021).
pubmed: 34168370
pmcid: 8434898
doi: 10.1038/s41590-021-00958-6
Wang, Y., Yin, C., Geng, L. & Cai, W. Immune infiltration landscape in clear cell renal cell carcinoma implications. Front. Oncol. 10, 491621 (2020).
pubmed: 33665156
doi: 10.3389/fonc.2020.491621
Zhang, S. et al. Immune infiltration in renal cell carcinoma. Cancer Sci. 110, 1564–1572 (2019).
pubmed: 30861269
pmcid: 6501001
doi: 10.1111/cas.13996
Monzon, F. A. et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod. Pathol. 24, 1470–1479 (2011).
pubmed: 21725288
pmcid: 4639322
doi: 10.1038/modpathol.2011.107
Massari, F. et al. Reprofiling metastatic samples for chromosome 9p and 14q aberrations as a strategy to overcome tumor heterogeneity in clear-cell renal cell carcinoma. Appl. Immunohistochem. Mol. Morphol. 25, 39–43 (2017).
pubmed: 26509904
doi: 10.1097/PAI.0000000000000257
Lin, E. et al. Integrative analysis of the genomic and immune microenvironment characteristics associated with clear cell renal cell carcinoma progression: implications for prognosis and immunotherapy. Front. Immunol. 13, 830220 (2022).
pubmed: 35677048
pmcid: 9168804
doi: 10.3389/fimmu.2022.830220
Wu, Y. et al. Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. Nat. Commun. 14, 1681 (2023).
pubmed: 36973268
pmcid: 10042888
doi: 10.1038/s41467-023-37211-7
Blumenfeld, M., Maury, M., Chouard, T., Yaniv, M. & Condamine, H. Hepatic nuclear factor 1 (HNF1) shows a wider distribution than products of its known target genes in developing mouse. Development 113, 589–599 (1991).
pubmed: 1685988
doi: 10.1242/dev.113.2.589
Davies, J. A. & Fisher, C. E. Genes and proteins in renal development. Exp. Nephrol. 10, 102–113 (2002).
pubmed: 11937757
doi: 10.1159/000049905
Muto, Y. et al. Single cell transcriptional and chromatin accessibility profiling redefine cellular heterogeneity in the adult human kidney. Nat. Commun. 12, 2190 (2021).
pubmed: 33850129
pmcid: 8044133
doi: 10.1038/s41467-021-22368-w
Liao, J. et al. Single-cell RNA sequencing of human kidney. Sci. Data 7, 4 (2020).
pubmed: 31896769
pmcid: 6940381
doi: 10.1038/s41597-019-0351-8
Nassar, A. H. et al. Epigenomic charting and functional annotation of risk loci in renal cell carcinoma. Nat. Commun. 14, 346 (2023).
pubmed: 36681680
pmcid: 9867739
doi: 10.1038/s41467-023-35833-5
Rheinbay, E. et al. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature 578, 102–111 (2020).
pubmed: 32025015
pmcid: 7054214
doi: 10.1038/s41586-020-1965-x
Wierenga, A. T. J. et al. HIF1/2-exerted control over glycolytic gene expression is not functionally relevant for glycolysis in human leukemic stem/progenitor cells. Cancer Metab. 7, 11 (2019).
pubmed: 31890203
pmcid: 6935105
doi: 10.1186/s40170-019-0206-y
Manshouri, R. et al. ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer. Nat. Commun. 10, 5125 (2019).
pubmed: 31719531
pmcid: 6851102
doi: 10.1038/s41467-019-12832-z
Si, W. et al. Dysfunction of the reciprocal feedback loop between GATA3- and ZEB2-nucleated repression programs contributes to breast cancer metastasis. Cancer Cell 27, 822–836 (2015).
pubmed: 26028330
doi: 10.1016/j.ccell.2015.04.011
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168
pmcid: 2705234
doi: 10.1093/bioinformatics/btp324
Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).
pubmed: 27270079
pmcid: 5027494
doi: 10.1093/nar/gkw520
Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).
pubmed: 30013179
pmcid: 6072608
doi: 10.1038/s41588-018-0165-1
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
pubmed: 19261174
pmcid: 2690996
doi: 10.1186/gb-2009-10-3-r25
Corces, M. R. et al. An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues. Nat. Methods 14, 959–962 (2017).
pubmed: 28846090
pmcid: 5623106
doi: 10.1038/nmeth.4396
Bailey, T. L. et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res. 37, W202–W208 (2009).
pubmed: 19458158
pmcid: 2703892
doi: 10.1093/nar/gkp335
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677
doi: 10.1093/bioinformatics/btt656
Yu, G., Wang, L. G. & He, Q. Y. ChIPseeker: an R/Bioconductor package for ChIP peak annotation, comparison and visualization. Bioinformatics 31, 2382–2383 (2015).
pubmed: 25765347
doi: 10.1093/bioinformatics/btv145
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
pubmed: 18798982
pmcid: 2592715
doi: 10.1186/gb-2008-9-9-r137
Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics 27, 1571–1572 (2011).
pubmed: 21493656
pmcid: 3102221
doi: 10.1093/bioinformatics/btr167
Burger, L., Gaidatzis, D., Schübeler, D. & Stadler, M. B. Identification of active regulatory regions from DNA methylation data. Nucleic Acids Res. 41, e155 (2013).
pubmed: 23828043
pmcid: 3763559
doi: 10.1093/nar/gkt599
Zhao, S. G. et al. The DNA methylation landscape of advanced prostate cancer. Nat. Genet. 52, 778–789 (2020).
pubmed: 32661416
pmcid: 7454228
doi: 10.1038/s41588-020-0648-8